Data from Two Phase III Studies of Merck & Co., Inc.'s Investigational Asthma Drug Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting

Published: Mar 02, 2010

NEW ORLEANS--(BUSINESS WIRE)--Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

Back to news